Eric Venker, an officer of Roivant Sciences Ltd., filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 187,943 common shares with an aggregate market value of $7,617,816.56, to be executed through Rockefeller Financial LLC on NASDAQ.
Key Highlights
- Proposed sale: Eric Venker, listed as an officer of Roivant Sciences Ltd. (NASDAQ:ROIV), intends to sell 187,943 common shares with an aggregate market value of $7,617,816.56.
- Approximate sale date: The filing lists November 10, 2026 as the approximate date of sale, to be executed through Rockefeller Financial LLC at 45 Rockefeller Plaza, Floor 5, New York, NY 10111.
- 10b5-1 plan: According to the filing, the shares will be sold pursuant to a Rule 10b5-1 trading plan adopted by Venker on June 30, 2026.
- Shares outstanding: The filing reports 724,561,460 common shares outstanding.
- Acquisition sources: The shares to be sold were acquired through options exercises (grant date April 20, 2022) and RSU vesting events under grants dated May 20, 2020 and May 20, 2021.
- Recent prior sales: The filing discloses six sales by Venker in the preceding three months totaling 1,013,909 shares, with gross proceeds ranging from $512,407.56 to $7,323,556.00 per transaction.
Venker's Proposed Sale: Share Sources and Recent Transaction History
According to the Form 144 filing, Eric Venker, identified as an officer of Roivant Sciences Ltd., proposes to sell 187,943 common shares on NASDAQ with an aggregate market value of $7,617,816.56. The broker named in the filing is Rockefeller Financial LLC. The filing was submitted on November 10, 2026, the same date listed as the approximate sale date.
The filing details the acquisition history of the shares to be sold. The securities were obtained through two separate options exercises tied to a grant dated April 20, 2022, with 51,725 shares acquired on March 20, 2025 and 17,351 shares acquired on February 13, 2025. Additional shares originated from RSU vesting events under Grant 018305 (grant date May 20, 2020) and Grant 018861 (grant date May 20, 2021), with vesting dates spanning from January 20, 2023 through November 20, 2024, according to the filing.
The filing also discloses six sales of common shares by Venker in the three months preceding the notice. Those transactions occurred on August 20, 2026 (13,909 shares, $512,407.56 gross proceeds), August 28, 2026 (200,000 shares, $7,147,087.91), September 30, 2026 (200,000 shares, $7,323,556.00), October 20, 2026 (200,000 shares, $7,023,153.39), October 28, 2026 (200,000 shares, $7,317,764.00), and November 3, 2026 (200,000 shares, $7,262,568.00). The filing states that all sales reported on this Form 144 will be made pursuant to the Rule 10b5-1 trading plan Venker adopted on June 30, 2026.
What Was Disclosed
Roivant Sciences Ltd. officer Eric Venker filed a Form 144 notice disclosing the proposed sale of 187,943 common shares valued at $7,617,816.56, to be conducted under a 10b5-1 plan adopted June 30, 2026, with Rockefeller Financial LLC serving as broker.




Please wait processing your request...